Oncternal Therapeutics announces agreement with FDA on phase 3 trial for zilovertamab
04 Janeiro 2022 - 6:27PM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024